Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kendle has acquired DecisionLine Clinical Research, a privately owned, early phase contract research organization with a state-of-the-art medical facility in Toronto, Canada.
Subscribe to our email newsletter
The acquisition brings to Kendle extensive world-class scientific expertise with psychopharmacology high-end exploratory or translational medicine capabilities, from first-in-human to proof-of-concept trial conduct, as well as drug development consulting, medical writing, data management, biostatistics and other support services.
Kendle acquired DecisionLine for an undisclosed cash amount. The acquired business will report into Philip Davies, vice president, Early Phase.
Simon Higginbotham, president of Kendle, said: “The addition of DecisionLine is an important step in building Kendle’s global capabilities for exploration of early phase drug candidates and supports our strategic initiative to drive growth in our Phase I business.”